for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Basilea Extends Phase 2 Study With Derazantinib In Intrahepatic Bile Duct Cancer

July 1 (Reuters) - BASILEA PHARMACEUTICA AG:

* BASILEA EXTENDS PHASE 2 STUDY WITH DERAZANTINIB IN INTRAHEPATIC BILE DUCT CANCER (ICCA) TO INCLUDE PATIENTS WITH FGFR2 GENE MUTATIONS OR AMPLIFICATIONS

* TOPLINE DATA FOR COHORT OF FGFR2 FUSION-POSITIVE PATIENTS ARE EXPECTED TO BE AVAILABLE AROUND MID-2020 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up